Celltrion Targets Global Partnerships at CPHI Worldwide 2025 in Frankfurt

News | 2025-10-24 15:05:43
[medi K / HEALTH IN NEWS] FRANKFURT — Celltrion, the South Korean biopharmaceutical giant, announced its participation in CPHI Worldwide 2025, held from October 28 to 30 in Frankfurt, Germany, with a strategic focus on expanding global partnerships.

Now in its 36th year, CPHI is the world’s largest pharmaceutical and biotechnology industry exhibition, drawing more than 60,000 professionals from over 170 countries.

Celltrion has secured a prominent 202-square-meter (approximately 61-pyeong) standalone booth along the main exhibition aisle to showcase its technological capabilities and competitive edge. The booth features dedicated meeting rooms and open collaboration spaces, alongside visitor engagement activities, including experiential events and branded giveaways.

Celltrion's CPHI Booth (Photo courtesy of Celltrion)
Celltrion's CPHI Booth (Photo courtesy of Celltrion)


The company is prioritizing reinforcement of existing supplier networks in overseas raw materials and active pharmaceutical ingredients, as well as contract manufacturing organization (CMO) partnerships, while accelerating the identification of new collaborators. The goal is to build a resilient supply chain amid growing global demand and an expanding product portfolio.
Celltrion has recently launched several new biosimilars, including Steqima and Aptoza for autoimmune diseases, Stoboclo-Osenbelt for bone disorders, and Omlicro for dermatological conditions, further diversifying its pipeline. Through its presence at CPHI, the company aims to strengthen production and marketing capabilities while exploring collaboration opportunities in novel modalities and automated manufacturing processes.

A Celltrion spokesperson stated, “By participating in CPHI, we plan to broaden global partnerships and highlight our technological competitiveness. With an expanded product portfolio and strategic collaborations, we will solidify our position in the global market.”

Kim Kuk Ju / press@themedik.kr
Copyright © 2020 mediK. All rights reserved.